#drugdiscovery

drugdiscovery

52 προβολές

3 άτομα συμμετέχουν στη συζήτηση

Δημοφ.

Πιο πρόσφατα

Mohammad_Haider90

·

--

💥 NVIDIA & Eli Lilly Invest $1B in AI Lab to Transform Drug Discovery
NVIDIA and Eli Lilly have announced a joint AI lab with a $1 billion investment over five years to revolutionize drug discovery and pharmaceutical manufacturing.
📌 Key Highlights:
• The lab will leverage advanced AI models and high-performance compute infrastructure to accelerate drug development.
• Goal: Create continuous AI-assisted experimental systems linking wet labs and dry labs, shortening development cycles and enhancing molecule validation.
• Combines Lilly’s pharma expertise and proprietary data with NVIDIA’s AI technologies, including digital twins, robotics, and advanced analytics.
• Focused on optimizing pharma manufacturing, clinical operations, and drug discovery pipelines.
This partnership bridges AI and biotech, promising faster, smarter, and more efficient approaches to bringing new medicines to patients.
#NVIDIA #EliLilly #DrugDiscovery #PharmaInnovation #Biotech #HealthcareTech

Longevity InTime

·

--

Άρθρο

BREAKING: Gero’s Quest to Stop Aging Just Secured a Potentially Multibillion-Dollar Pharma DealWe’ve signed a global joint research and license agreement with Chugai Pharmaceutical (a member of the Roche Group)—one of the world’s leading drug developers. This is more than a partnership. It’s a major validation of our science, our model, and our mission to radically extend healthy lifespan. * Deal Overview Multi-million upfront payment Up to $250 million in development and sales milestones Royalties on future commercial sales Exclusive global rights for Chugai to develop antibody drugs targeting aging, based on Gero’s AI-discovered targets And this is only the beginning—our platform has already uncovered many more transformative targets in a multi-target pipeline. * Why This Matters Aging is the single biggest risk factor behind most chronic diseases. Yet no approved therapy exists that can meaningfully slow, stop, or reverse it. At Gero, we’ve built something different: A physics-informed AI platform that models human aging as a dynamic system—unlocking therapeutic targets that others can’t see. Our Large Health Model (LHM) is trained on real-world health trajectories from over 10 million U.S. and U.K. patients, curated from a broader pool of 100+ million electronic medical records. It clusters chronic diseases into dozens of molecular programs, identifying multi-disease targets for aging-driven conditions. Our generative AI engine, ProtoBind-Diff, designs drug-like molecules for previously inaccessible targets—in a matter of days. These technologies are backed by peer-reviewed publications in Science, Nature Communications, Aging Cell, and more. Our inspiration comes from nature itself—from species like naked mole rats and bats, which show little to no signs of aging over long lifespans. Progress is accelerating. The success of GLP-1 drugs (Ozempic, Wegovy) has shown what’s possible: a single class of molecules improving metabolic health, heart disease, and obesity. What once seemed like science fiction is becoming reality. #TrumpTariffs Pfizer #DrugDiscovery #PhysicsAndBiology #Gerophysics #Healthspan

BREAKING: Gero’s Quest to Stop Aging Just Secured a Potentially Multibillion-Dollar Pharma Deal

We’ve signed a global joint research and license agreement with Chugai Pharmaceutical (a member of the Roche Group)—one of the world’s leading drug developers.

This is more than a partnership. It’s a major validation of our science, our model, and our mission to radically extend healthy lifespan.

* Deal Overview

Multi-million upfront payment
Up to $250 million in development and sales milestones
Royalties on future commercial sales
Exclusive global rights for Chugai to develop antibody drugs targeting aging, based on Gero’s AI-discovered targets
And this is only the beginning—our platform has already uncovered many more transformative targets in a multi-target pipeline.

* Why This Matters

Aging is the single biggest risk factor behind most chronic diseases. Yet no approved therapy exists that can meaningfully slow, stop, or reverse it.

At Gero, we’ve built something different:

A physics-informed AI platform that models human aging as a dynamic system—unlocking therapeutic targets that others can’t see.
Our Large Health Model (LHM) is trained on real-world health trajectories from over 10 million U.S. and U.K. patients, curated from a broader pool of 100+ million electronic medical records.
It clusters chronic diseases into dozens of molecular programs, identifying multi-disease targets for aging-driven conditions.
Our generative AI engine, ProtoBind-Diff, designs drug-like molecules for previously inaccessible targets—in a matter of days.
These technologies are backed by peer-reviewed publications in Science, Nature Communications, Aging Cell, and more.
Our inspiration comes from nature itself—from species like naked mole rats and bats, which show little to no signs of aging over long lifespans.

Progress is accelerating. The success of GLP-1 drugs (Ozempic, Wegovy) has shown what’s possible: a single class of molecules improving metabolic health, heart disease, and obesity. What once seemed like science fiction is becoming reality.
#TrumpTariffs Pfizer #DrugDiscovery #PhysicsAndBiology #Gerophysics #Healthspan

Συνδεθείτε για να εξερευνήσετε περισσότερα περιεχόμενα